Conflict of interest: the authors declare that they have no conflicts of interest.
Experimental dermatology ● Concise report
Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis
Article first published online: 13 NOV 2013
© 2013 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 39, Issue 3, pages 385–390, April 2014
How to Cite
Bosè, F., Capsoni, F., Molteni, S., Raeli, L., Diani, M., Altomare, A., Garavaglia, M., Garutti, C., Frigerio, E., Banfi, G., Altomare, G. and Reali, E. (2014), Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis. Clinical and Experimental Dermatology, 39: 385–390. doi: 10.1111/ced.12251
- Issue published online: 18 MAR 2014
- Article first published online: 13 NOV 2013
- Manuscript Accepted: 12 AUG 2013
- INGM (Istituto Nazionale di Genetica Molecolare)
- Pfizer Italia
The differences in systemic T-cell responses between patients with psoriatic arthritis (PsA) and patients with cutaneous psoriasis (Ps) are still largely unknown. To determine differential features that could be used to distinguish PsA from Ps, we compared the cytokine secretion profile of circulating T cells in patients with PsA, patients with cutaneous Ps and control subjects. We determined Th1, Th2 and Th17 cytokine secretion of anti-CD3-stimulated peripheral blood mononuclear cells (PBMCs) using a cytokine bead array. Normality of data distribution was assessed by the Shapiro–Wilk test, and statistical significance was calculated by the Mann–Whitney test. Phenotypic characterization of circulating T cells was performed by fluorescence-activated cell sorting analysis. We found that the major systemic differences distinguishing PsA from cutaneous Ps were the increased secretion of interleukin (IL)-2 by α-CD3-stimulated PBMCs and a higher percentage of circulating CD3+ T cells expressing the proliferation marker CD71 in PsA. These results indicate IL-2 as a possible biomarker of PsA, and suggest a role of circulating T cells with high proliferative capacity in the pathogenesis of PsA.